Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Neurocrine Biosciences (NBIX)

Neurocrine Biosciences Reports Third-Quarter 2026 Total Revenues of $1.1 Billion

Positive Impact 4 of 5 earnings

Neurocrine Biosciences reported third-quarter 2026 total revenues of $1.1 billion, representing 41% year-over-year growth, alongside GAAP net income of $207 million. The company also raised its full-year 2026 net sales guidance for INGREZZA to a range of $2.9 billion to $2.925 billion.

Key points

  • Total revenues for the third quarter of 2026 reached $1.1 billion, up 41% compared to $795 million in the third quarter of 2025.
  • INGREZZA net product sales were $801 million, leading management to raise full-year 2026 INGREZZA net sales guidance to $2.9 billion to $2.925 billion.
  • GAAP net income for the third quarter of 2026 was $207 million, or $1.96 per diluted share, compared to $210 million, or $2.04 per diluted share, in the prior-year period.

The filing

CompanyNeurocrine Biosciences (NBIX)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:11 PM ET
Accession number0000914475-26-000053

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 3, 2026, 8:16 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.